Drugmakers Doubt AI Cure Promise; No FDA-Cleared AI-Designed Drug

Silicon Valley technology leaders are increasingly promoting artificial intelligence as a transformative force in medicine, promising faster discovery and potential cures for disease. But senior executives at pharmaceutical companies are expressing skepticism, arguing that the sector has not yet delivered on regulatory proof of AI’s impact. According to drugmaker leaders, no drug discovered or designed with the assistance of AI has received clearance from the U.S. Food and Drug Administration. They contend that biology, not computation, remains the central obstacle. Complex living systems, disease mechanisms, and clinical outcomes are difficult to model accurately with current AI tools, and the industry must still contend with uncertainty around safety, efficacy, and biological complexity. The tension highlights a growing gap between tech-sector ambition and pharmaceutical industry reality. While AI is attracting investment and generating expectations of major breakthroughs, pharma executives are emphasizing that approved medicines, not algorithms, are the measure of success in drug development.